Inventiva (NASDAQ:IVA) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Financial Analysis

Kiora Pharmaceuticals (NASDAQ:KPRX) and Inventiva (NASDAQ:IVA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Kiora Pharmaceuticals and Inventiva, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1	0	1	0	2.00
Inventiva	1	0	7	3	3.09

Kiora Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 284.62%. Inventiva has a consensus price target of $16.56, indicating a potential upside of 247.81%. Given Kiora Pharmaceuticals’ higher probable upside, equities analysts plainly believe Kiora Pharmaceuticals is more favorable than Inventiva.

Institutional & Insider Ownership

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Kiora Pharmaceuticals has a beta of -0.38, indicating that its share price is 138% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Kiora Pharmaceuticals and Inventiva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Inventiva	N/A	N/A	N/A

Earnings and Valuation

This table compares Kiora Pharmaceuticals and Inventiva”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02 million	0.72	-$10.84 million	($2.51)	-1.04
Inventiva	$5.07 million	195.01	-$400.67 million	N/A	N/A

Kiora Pharmaceuticals has higher revenue and earnings than Inventiva.

Summary

Inventiva beats Kiora Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.